Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — H1 2022 Earnings Presentation
35 slides from Nxera Pharma's earnings presentation, Aug 10, 2022
Slide 1: H1 FY2022 Financial Results
NON-CONFIDENTIAL H1 FY2022 Financial Results Six-month period ended June 30, 2022 August 10, 2022 | Sosei Group Corporation (TSE:4565)
Slide 2: Disclaimer
Disclaimer The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed
Slide 3: Agenda
Agenda 1 Financial Results 2 Operational Highlights 3 R&D Progress 4 Objectives for FY2022 5 Q&A 6 Appendix Note: This material was created to explain the details of our company and is not intended to be used for investment decisions. In addition, the contents reflect the views of our company at the
Slide 4: Financial Results
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal 1 Financial Results Hironoshin Nomura, CFO 4
Slide 5: Financial Summary for H1 2022
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Financial Summary for H1 2022 Successful execution of strategy with continuing investment in R&D H1 Revenue of ¥2,457m ($20m) vs. ¥3,123m ($29m) in the prior comparative period. H1 2022 1 includes two mi
Slide 6: Key Financial Indicators
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Key Financial Indicators There were lower number of milestone events until end of June, compared with FY21 (JPY million) Revenue Revenue can vary significantly quarter on quarter depending on the occur
Slide 7: Full year cost guidance (Updated)
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Full year cost guidance (Updated) Incremental investment designed to deliver greater returns over the medium to long term Updated Guidance R&D expenses (IFRS basis) (JPY million) 8,000 7,750 ¥6,750m to ¥
Slide 8: Operational Highlights
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal 2 Operational Highlights Chris Cargill, CEO 8
Slide 9: Strong execution across all phases/collaboration types
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Strong execution across all phases/collaboration types Updates (H1) Post H1 event Pre-Disc. / Discovery Preclinical studies Phase 1 Phase 2 Marketed ✓ ✓ ✓ Ultibro® Breezhaler® Multi-target Multi-target M
Slide 10: Strong execution across all phases/collaboration types (cont’d)
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Strong execution across all phases/collaboration types (cont’d) Discovery Research Innovation Updates Translational Medicine/Clinical Development Updates New GPCR targets already Strong GLP-1 Ph. 1 data,
Slide 11: New multi-target Neurology collaboration with AbbVie
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal New multi-target Neurology collaboration with AbbVie Post H1 event US$80m in upfront and near-term revenues, plus up to US$1.2bn in future milestone revenues Balance of potential milestone income from ex
Slide 12: EP4 antagonist (HTL0039732)
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal EP4 antagonist (HTL0039732) Post H1 event New collaboration with CRUK to advance clinical trials for this promising cancer therapeutic Best access - unrivalled network of world-leading scientists and cli
Slide 13: Advancing four wholly-owned programs
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Advancing four wholly-owned programs Advancing priority programs into early clinical studies, including collaboration with CRUK Indication and Schizophrenia Atopic Immunosuppression Inflammatory target a
Slide 14: R&D Progress
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal 3 R&D Progress Dr. Matt Barnes, President of Heptares and Head of UK R&D 14
Slide 15: Muscarinic M4 agonist (NBI-1117568)
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Muscarinic M4 agonist (NBI-1117568) Post H1 event Collaboration with Neurocrine, announced IND of Ph2 study trigger $30 million milestone Source: Neurocrine Biosciences Announces Conference Call and Webc
Slide 16: GLP-1 agonist (PF-07081532)
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal GLP-1 agonist (PF-07081532) Post H1 event Pfizer highlights potentially best-in-class data to be presented at EASD (19-23 September) Source: Pfizer Quarterly Corporate Performance – Second Quarter 2022 p
Slide 17: Multi-target Collaboration Partners
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Multi-target Collaboration Partners Updates (H1) Post H1 event Making excellent progress with new and long-term partnered programs Partner Execution Therapeutic Area Stage Progress x3 clinical stage asse
Slide 18: Strategic collaboration landscape
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Strategic collaboration landscape Updates (H1) Adding complementary approaches to increase discovery opportunities Pre-Disc. / Discovery Preclinical studies Clinical studies Commercialization Target ID S
Slide 19: Strategic collaboration partners
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Strategic collaboration partners Updates (H1) Identification and validation of novel GPCR targets for new discovery programs ✓ ✓ 2021~ 2022~ 2022~ AI drug discovery (Target) AI drug discovery (Target) Gu
Slide 20: Objectives for FY2022
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal 4 Objectives for FY2022 Chris Cargill, CEO 20
Slide 21: Priority objectives for FY2022
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Priority objectives for FY2022 Excellent progress YTD across our business FY2022 OBJECTIVES UPDATES Execute at least one new high value collaboration 1 and/or co-investment ✓ US$80m in upfront and near-t
Slide 22: Mid to long-term direction for accelerating our growth
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Mid to long-term direction for accelerating our growth World-class science and Translational Medicine expansion to build long-term value Historic and planned corporate value expansion Example of partners
Slide 23: Q&A
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal 5 Q&A 23
Slide 24: Appendix
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal 6 Appendix 24
Slide 25: EP4 antagonist (HTL0039732)
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal EP4 antagonist (HTL0039732) Post H1 event Clinical Development Partnership with CRUK to advance potential best-in-class therapeutic Partnership enables us to cost effectively access the most advanced can
Slide 26: Introduction of ‘Core Operating Profit’
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Introduction of ‘Core Operating Profit’ Core Operating Profit – the financial indicator closer to the reality of our business Operating Profit Operating Profit “IFRS” “Core” Financial results recorded
Slide 27: Partnered pipeline
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Partnered pipeline Updates (H1) Post H1 event Compound Target / Mechanism of Action Modality Indication Partner Disc. PCC Ph1 Ph2 Ph3 App Mkt Out-licensing Collaborations Seebri® Breezhaler® LAMA SME COP
Slide 28: Partnered pipeline (cont’d)
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Partnered pipeline (cont’d) Updates (H1) Post H1 event Compound Target / Mechanism of Action Modality Indication Partner Disc. PCC Ph1 Ph2 Ph3 App Mkt Co-development KY1051 CXCR4 mAb mAb Immuno-oncology
Slide 29: In-house pipeline
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal In-house pipeline Compound Target / Mechanism Modality Indication Originator Disc. PCC Ph1 Ph2 Ph3 App Mkt In-house Programs Not disclosed H4 antagonist SME Atopic Dermatitis HTL0039732 EP4 antagonist SM
Slide 30: Our partnered candidates target significant market opportunities
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Our partnered candidates target significant market opportunities Multi-billion USD annual peak sales potential for our post-pre-clinical pipeline Peak Sales(USD million) Number of Category Indication2 Ou
Slide 31: Potential revenues from existing partnerships
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Potential revenues from existing partnerships Securing stable revenues in the short to medium term from existing partnerships Potential milestones from existing partners Potential royalties from existing
Slide 32: Major licensing transactions
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Major licensing transactions New multi-target collaboration for Neurological disorders with AbbVie signed in August 2022 Upfront and Initial Potential Total Partner Execution Program Therapeutic Area(s)
Slide 33: Glossary
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Glossary Basic Terminology/Technology GPCR G Protein-Coupled Receptor There are about 800 types of GPCRs in the human body. While 400 of them are known to be potential drug targets, about 300 of them are
Slide 34: Glossary (cont’d)
1. Financial 2. Operational 3. R&D 4. FY2022 5. Q&A 6. Appendix Results Highlights Progress Goal Glossary (cont’d) Drug discovery target M1 Muscarinic M1 Receptor One of the five subtypes M1 to M5 of muscarinic acetylcholine receptors, known to be involved in learning and memory. M4 Muscarinic M4 Re
Slide 35: Locations
Locations SOSEI HEPTARES PMO Hanzomon 11F Steinmetz and Cori Buildings North West House 2-1 Kojimachi, Chiyoda-ku Granta Park, Cambridge 119 Marylebone Road Tokyo 102-0083 CB21 6DG London NW1 5PU Japan United Kingdom United Kingdom